



Integra LifeSciences Launches INTEGRA(TM) Matrix Wound Dressing at Plastic Surgery 2004 in Philadelphia

PLAINSBORO, N.J., Oct. 12, 2004 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the launch of the INTEGRA™ Matrix Wound Dressing, a single layer version of its advanced wound care product line that can be used for the management of partial and full-thickness soft tissue wounds. Integra LifeSciences is introducing the INTEGRA™ Matrix Wound Dressing this week at the American Society of Plastic Surgeon's Annual Meeting in Philadelphia, Pennsylvania, and will sell the product in the United States through its plastic and reconstructive surgery sales force.

The INTEGRA™ Matrix Wound Dressing is a single layer tissue engineered matrix, part of a family of products that includes the INTEGRA® Dermal Regeneration Template and the INTEGRA™ Bilayer Matrix Wound Dressing. It is an advanced wound care device constructed of a complex biodegradable matrix of cross-linked collagen and glycosaminoglycan. This porous material provides a scaffold for cellular invasion and capillary growth. The scaffold is eventually remodeled as the patient's cells rebuild the damaged site.

The INTEGRA™ Matrix Wound Dressing is indicated for the management of wounds including: partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, Post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds. The product has exceptional strength and flexibility and can be stored at room temperature. It will be available in four sizes: 2 inch by 2 inch, 4 inch by 5 inch, 4 inch by 10 inch and 8 inch by 10 inch. Integra estimates that the market opportunity for products used to treat trauma and chronic wounds is approximately \$400 million.

"Plastic and reconstructive surgeons currently using our INTEGRA Dermal Regeneration Template and INTEGRA Bilayer Matrix Wound Dressing have requested that we introduce an INTEGRA Matrix without the silicone layer, to allow them greater flexibility in using our tissue regenerative products," said Tom Tarca, Integra's Vice President of Marketing, Plastic and Reconstructive Surgery. "The INTEGRA™ Matrix Wound Dressing addresses that request, enhancing our customers' treatment options, and provides an example of Integra's ability to respond to the needs of physicians."

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (<http://www.Integra-LS.com>).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the use of our INTEGRA Matrix Wound Dressing. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use the INTEGRA Matrix Wound Dressing may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors Than May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT:

Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@Integra-LS.com

Maria Platsis
Director of Corporate Development and Investor Relations
(609) 936-2333
mplatsis@Integra-LS.com